Brinzolamide
- Generic Name
- Brinzolamide
- Brand Names
- Azarga, Azopt, Simbrinza
- Drug Type
- Small Molecule
- Chemical Formula
- C12H21N3O5S3
- CAS Number
- 138890-62-7
- Unique Ingredient Identifier
- 9451Z89515
- Background
Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase II (CA-II) inhibitor indicated to reduce ocular pressure in patients with ocular hypertension or open-angle glaucoma. Although the exact pathophysiology of glaucoma is still unknown, one of the main hallmarks of this disease is vascular dysregulation and abnormalities. The resu...
- Indication
Brinzolamide, either as a standalone agent or in combination with brimonidine, is approved by the FDA for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Brinzolamide is also approved in Europe to be used in combination with timolol to treat the same conditions.
- Associated Conditions
- Increased Intra Ocular Pressure (IOP)
- Associated Therapies
- -
Stop Retinal Ganglion Cell Dysfunction Study
- Conditions
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 500
- Registration Number
- NCT02390284
- Locations
- 🇺🇸
Bascom Palmer Eye Institute - University of Miami, Miami, Florida, United States
Efficacy Comparison of Xalatan and Azopt on POAG and OH
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2010-03-11
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 130
- Registration Number
- NCT01084902
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.